Bloomberg Law
March 23, 2023, 4:16 PM

NIH Decision on Licensing of Cancer Drug Xtandi Appealed

Jeannie Baumann
Jeannie Baumann

Advocates for lowering the cost of prostate cancer Xtandi by reclaiming US patents are appealing a decision by the National Institutes of Health not to intervene on Pfizer Inc. and Astellas Pharma Inc. licenses.

The appeal, which was provided Thursday to Bloomberg Law, comes two days after NIH declined a petition to initiate what’s known as march-in proceedings on Xtandi. Established under the Bayh-Dole Act, march-in allows the government to seize patents for inventions created with government funding and license them to other entities for commercialization.

Robert Sachs, a cancer patient and one of the petitioners for the march-in ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.